Photo by iamthedave from unsplash
We are very grateful to our distinguished colleague for his constructive comments.1 However it seems that some keypoints of our study were grossly misunderstood.2 As clearly stated, the objective of… Click to show full abstract
We are very grateful to our distinguished colleague for his constructive comments.1 However it seems that some keypoints of our study were grossly misunderstood.2 As clearly stated, the objective of the CONCEPT study was to confirm that chondroitin sulfate (CS) is superior to placebo (PLB) in the symptomatic treatment of osteoarthritis, with the addition of a Celebrex (CLB) arm, as requested by the European Medicines Agency, to provide an external validation and to better assess the relevance of the difference in pain relief observed between the CS and PLB arms. There was no intent to demonstrate a non-inferiority of CS versus Celebrex. In such a case, a non-inferiority margin for the comparison would be mentioned in the protocol, and the power calculation would be substantially different. The use of the word similar in describing Visual Analogue Scale (VAS) and Lequesne scoring …
Journal Title: Annals of the Rheumatic Diseases
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!